A (non-exhaustive) survey of new and existing technologies for the monitoring of wastewater treatment plants is presented. Emphasis is given to the way these sensors can provide insight in the ongoing (bio-) processes. Three different uses for sensors can be found: for monitoring (operator support), in automatic control systems and as tools for plant auditing/optimization/modelling by consultants. From this, sensors have been classified in two basic types: (i) reliable, simple and low maintenance sensors for day-to-day monitoring and control and (ii) advanced, higher maintenance sensors that are used in auditing, model calibration and optimisation. The paper is organized according to the typical unit processes of biological wastewater treatment systems: anaerobic digestion, activated sludge, nutrient removal and sedimentation. Attention is drawn to a number of practical problems associated with the use of sophisticated sensors in the harsh (dirty) conditions of wastewater treatment processes. The use of autocalibration and built-in sensor checks, cleaning systems and reliable sample preparation units is illustrated. The paper ends with a discussion of the applicability of the different sensors.
A systematic approach to determine the optimal operation strategy for nitrogen (N) and phosphorus (P) removal of sequencing batch reactors (SBRs) has been developed and applied successfully to a lab-scale SBR. The methodology developed is based on using a grid of possible scenarios to simulate the effect of the key degrees of freedom in the SBR system. The grid of scenarios is simulated using a calibrated ASM2dN model developed and calibrated in a previous study. Effluent quality in combination with a robustness index for each of the scenarios is used to select the best scenario. With the best scenario, it is possible to improve/increase the current performance of the SBR system by around 54% and 74% for N and P removal respectively.
The current study was carried out to define the involvement of Peroxiredoxin (Prx) II in progression of hepatocellular carcinoma (HCC) and the underlying molecular mechanism(s). Expression and function of Prx II in HCC was determined using H-ras(G12V)-transformed HCC cells (H-ras(G12V)-HCC cells) and the tumor livers from H-ras(G12V)-transgenic (Tg) mice and HCC patients. Prx II was upregulated in H-ras(G12V)-HCC cells and H-ras(G12V)-Tg mouse tumor livers, the expression pattern of which highly similar to that of forkhead Box M1 (FoxM1). Moreover, either knockdown of FoxM1 or site-directed mutagenesis of FoxM1-binding site of Prx II promoter significantly reduced Prx II levels in H-ras(G12V)-HCC cells, indicating FoxM1 as a direct transcription factor of Prx II in HCC. Interestingly, the null mutation of Prx II markedly decreased the number and size of tumors in H-ras(G12V)-Tg livers. Consistent with this, knockdown of Prx II in H-ras(G12V)-HCC cells reduced the expression of cyclin D1, cell proliferation, anchorage-independent growth and tumor formation in athymic nude mice, whereas overexpression of Prx II increased or aggravated the tumor phenotypes. Importantly, the expression of Prx II was correlated with that of FoxM1 in HCC patients. The activation of extracellular signal-related kinase (ERK) pathway and the expression of FoxM1 and cyclin D1 were highly dependent on Prx II in H-ras(G12V)-HCC cells and H-ras(G12V)-Tg livers. Prx II is FoxM1-dependently-expressed antioxidant in HCC and function as an enhancer of Ras(G12V) oncogenic potential in hepatic tumorigenesis through activation of ERK/FoxM1/cyclin D1 cascade.
Radioisotope-labelled lipiodol has been used in the therapy of liver cancer. Recently a lipiodol solution of 188Re-labelled diaminedithiol (DD) has been reported to show a high uptake in the liver cancer. We synthesized long-chain alkyl DD derivatives to improve their uptake and retention in tissue. As the length of the alkyl chain increased, tissue uptake and retention also increased due to hydrophobic interaction with lipiodol. Among the synthesized compounds, the lipiodol solution of 188Re-HDD, the DD derivative with the longest side chain (C16), is a promising agent for therapy of liver cancer.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.